{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"BioBreakthroughs","title":"#50 - Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/a9067c4f\"></iframe>","width":"100%","height":180,"duration":1237,"description":"Join us on the latest episode! Our Guest: Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation.What you'll get out of this episode:PDS Biotechnology targets the key limitations of CAR T and cancer vaccine therapies using lipid nanoparticle-based immunotherapy.Their lead candidate, PDS0101, demonstrated over 2x improvement in survival for HPV-positive head and neck cancer.The platform technology shows consistent efficacy across multiple independent Phase 2 trials.Late-stage clinical programs focus on HPV16+ head and neck cancer, with additional trials for colorectal, prostate, and MUC1+ cancers.To Learn More About Our Guest And Their Company:Guest LinkedIn https://www.linkedin.com/in/frank-bedu-addo-4797947/Company LinkedIn https://www.linkedin.com/company/pds-biotechnology-corporation/ Website https://www.pdsbiotech.com/ Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/","thumbnail_url":"https://img.transistorcdn.com/roxGfgcNItysBs3fg55SsdSx4l_Pbz86Ktm2KMDYkR4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQwNjg1LzE2ODE5/MzQxODQtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}